Rat CD86 / B7-2 Protein (His Tag)

Rat B-lymphocyte Activation Antigen B7-2 Protein

Rat CD86 / B7-2 Protein Product Information

• Synonym: B7-2
• Protein Construction: A DNA sequence encoding the rat CD86 ( NP_064466.1 ) extracellular domain ( Met 1 - Ile 250 ) was expressed, fused with a polyhistidine tag at the C-terminus
• Source: Rat
• Expression Host: Human Cells

Rat CD86 / B7-2 Protein QC Testing

• Purity: > 95 % as determined by SDS-PAGE
• Bio-activity: Measured by its binding ability in a functional ELISA
  Immobilized rat CD86 at 2 μg/ml ( 100 μl/well ) can bind mouse CD28 with a linear ranger of 6.4 - 160 ng/ml
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Pro 30
• Molecular Mass: The recombinant rat CD86 comprises 232 amino acids and predicts a molecular mass of 26.8 kDa. The apparent molecular mass of the rat CD86 is approximately 40-70 kDa in SDS-PAGE under reducing conditions due to glycosylation
• Formulation: Lyophilized from sterile PBS , pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: CD86 protein

Rat CD86 / B7-2 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Rat CD86 / B7-2 Protein Description

Rat CD86, also known as B-lymphocyte activation antigen B7-2 (referred to as B70), is a member of the cell surface immunoglobulin superfamily and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. B7-2 exists predominantly as a monomer on cell surfaces and interacts with two co-stimulatory receptors CD28 and cytotoxic T lymphocyte -associated antigen 4 (CTLA-4) expressed on T cells, and thus induces the signal pathways which regulate T cell activation and tolerance, cytokine production, and the generation of CTL. CD28 has two ligands expressed largely on professional APC, named B7-1 (CD80) and B7-2 (CD86). They are both type I  transmembrane proteins with a membrane distal IgV and a membrane proximal Ig constant (IgC) domain and share 25% sequence identity. Although interacting with the same receptors, B7-1 and B7-2 show several distinct features. Binding of B7-2 with CD28 induces the activation of T cell, whereas CTLA-4 acts as a negative regulator and diminishes the immune responses. It is indicated that contacts between B and T helper cells mediated by CD86 encourage signals for the proliferation and IgG secretion of normal B cells and B cell lymphomas. Recent study has revealed that CD86 also promotes the generation of a mature APC repertoire and promotes APC function and survival. CD86 has an important role in chronic hemodialysis, allergic pulmonary inflammation, arthritis, and antiviral responses, and thus is regarded as a promising candidate for immune therapy.

References

1. Freeman, G.J. et al., 1993, J Exp Med. 178 (6): 2185-92.
2. Mark, D.A. et al., 1998, Int Immunol. 10 (11): 1647-55.
3. Girndt, M. et al., 2001, Kidney Int. 59 (4): 1382-9.
4. Tikkanen, J.M. et al., 2002, Am J Respir Crit Care Med. 165 (5): 724-9.
5. O'Neill, S.K. et al., 2007, J Immunol. 179 (8): 5109-16.
6. Salek-Ardakani, S. et al., 2009, J Immunol. 82 (5): 2909-1918.